Search clinical trials for: SHR-1501

Total 4565 results

Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

China
University of Chicago
Juvenile Diabetes Research Foundation; Cure Alliance

Recruiting

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Diabetes Mellitus

United States
Eledon Pharmaceuticals

Recruiting

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Kidney Transplant

Canada, Australia, United Kingdom
Anelixis Therapeutics, LLC

Completed

Multiple Doses of AT-1501-A201 in Adults With ALS

Amyotrophic Lateral Sclerosis

United States, Canada
Anelixis Therapeutics, LLC

Withdrawn

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

Type 1 Diabetes Mellitus

Canada
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Pancreatic Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety, Tolerability and PK of SHR1314 in axSpA

Axial Spondyloarthritis

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

Familial Hypercholesterolemia
Centocor, Inc.

Completed

A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects

Healthy

China
Aminex Therapeutics, Inc.
Iqvia Pty Ltd; Novella Clinical

Withdrawn

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

Neoplasms | Tolerance | Medication Toxicity

United States
Tehran University of Medical Sciences
Iran University of Medical Sciences

Unknown

Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)

Optic Nerve Diseases

Iran, Islamic Republic of
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Eledon Pharmaceuticals

Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

IgA Nephropathy | IgAN

Australia, Spain, Thailand, New Zealand, Croatia, Malaysia, Philippines, Poland, Sri Lanka, United Kingdom
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Apollomics (Australia) Pty. Ltd.
Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...

Terminated

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Renal Cell Carcinoma | Hepatocellular Carcinoma

Australia, New Zealand
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Gilead Sciences

Completed

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Mixed Hyperlipidemia | Non-familial Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Chemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous Cell

China
Gilead Sciences

Completed

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Gilead Sciences

Terminated

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Spain, Belgium, Canada, United Kingdom, Australia, Denmark, Poland, Ireland, France, Sweden
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Cholangiocarcinoma | Biliary Tract Cancer

China
Stragen France

Completed

First-In-Human PainCart Study for STR-324

Pain

Netherlands
Gilead Sciences

Terminated

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Sunhawk Vision Biotech, Inc.

Completed

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

Myopia

Taiwan
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Takara Bio Inc.

Active, not recruiting

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (TBI-1501)

Lymphoblastic Leukemia, Acute Adult

Japan
Hospital Clinic of Barcelona

Unknown

Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone

Other Complications Associated With Artificial Fertilization

Spain
Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Not yet recruiting

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

HER2 Low Advanced or Metastatic Breast Cancer
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
West China Hospital

Not yet recruiting

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer

Search clinical trials for: SHR-1501

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations